2. Loser: GlaxoSmithKline

Company: GlaxoSmithKline
Symbol: $GSK
Beginning Price: 1484.50 pence
Ending Price: 1347 pence
Loss: 9.26%

As February dawned at GlaxoSmithKline ($GSK), CEO Andrew Witty gave investors a pep talk. This would be the year that GSK returned to real sales growth--none of the "underlying" kind of growth you talk about during the worst of the patent cliff. "We feel like we are moving into a new era," Witty said at the time.

But the stars aligned in a different direction. Deep price cuts in Europe and generic competition in the U.S. offset solid growth in emerging markets and consumer healthcare, pushing second- and third-quarter revenues down instead of up. "[N]o cause for optimism," Witty said about Europe, adding that he hoped it wasn't "the new normal."

GSK has made forward strides--both in wrapping up old problems and taking on new opportunities. But since a high in August, the company's London-traded shares have been moving downward, with a big slide around the time those disappointing Q3 sales were announced. The question now is whether Witty's sunny outlook returns by year's end--and whether investors come along for the ride.

For more:
Pharma fights European austerity with product pullbacks
Exec says GSK is back on the straight and narrow
Glaxo sales slump in Europe, U.S. on price cuts, generics
Hang on just a bit longer for sales growth, GSK chief says

 

 

 

 

2. Loser: GlaxoSmithKline
Read more on

Suggested Articles

JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.

Rather than "we did the best we could," Vas Narasimhan, during an internal call with managers, said Novartis could have handled the Zolgensma crisis…

After five years of struggles, Sun Pharmaceutical has put the problems at its key plant in Halol, India behind it.